Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
08/01/2022 - 08:00 AM
SAN FRANCISCO --(BUSINESS WIRE)--
Blade Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins , M.D., president and CEO, will participate in the “Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need” panel discussion on Tuesday, August 9, 2022 , 1:00 pm (ET) , during the 2022 BTIG Biotechnology Conference , August 8 – 9, in New York City . Blade’s lead investigational medicine is cudetaxestat, a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial in patients with idiopathic pulmonary fibrosis.
This conference is being hosted by BTIG, a global financial services firm specializing in institutional trading, investment banking, research, and related brokerage services. BTIG’s Corporate Access program hosts client events across the consumer, digital assets, energy and infrastructure, financials, healthcare, real estate, and technology sectors. To join the conference, email info@btig.com .
About Blade Therapeutics
Blade Therapeutics, Inc autotaxin / LPA and calpain biology – that are foundational to cell- and tissue-damage responses associated with fibrosis and neurodegeneration . Blade’s focused approach offers the potential to produce disease-modifying, life-saving therapies. Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and an inhibitor of dimeric calpains. Visit www.blademed.com for more information and follow Blade on LinkedIn .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220801005047/en/
Michael Blash (Blade) – Media
mblash@blademed.com | +1-650-453-0632
Krishna Gorti , M.D. (Blade) – Investors
kgorti@blademed.com | +1-973-570-9438
Source: Blade Therapeutics, Inc.
BIOTU Rankings
N/A Ranked by Stock Gains
BIOTU Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About BIOTU
Biotech Acquisition Company, a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. Although the Company may pursue a business target in any industry or geographic location, the Company intends to focus its search for a target business in the healthcare sector. The Company believes that this focus will complement its sponsor’s and management team’s background as affiliates of SPRIM Global Investments, a leading life science investment firm in the healthcare industry. The Company expects that its target sector will have a particular focus on life sciences/ biotechnology, healthcare information technology, medical technology and technology-enabled healthcare service sectors.
